- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | EXTRAWELL PHAR (00858): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 27.03. | EXTRAWELL PHAR (00858): MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS | - | HKEx | ||
| 17.03. | EXTRAWELL PHAR (00858): COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION ... | - | HKEx | ||
| 27.02. | EXTRAWELL PHAR (00858): (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN ... | - | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 20.01. | EXTRAWELL PHAR (00858): CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 31.12.25 | EXTRAWELL PHAR (00858): CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY ... | 3 | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.12.25 | EXTRAWELL PHAR (00858): CHANGE OF CHIEF EXECUTIVE OFFICER | 3 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2025/26 | 2 | HKEx | ||
| 22.12.25 | EXTRAWELL PHAR (00858): INTERIM REPORT 2025/26 | 1 | HKEx | ||
| 19.12.25 | EXTRAWELL PHAR (00858): GRANT OF SHARE OPTIONS | 2 | HKEx | ||
| 02.12.25 | EXTRAWELL PHAR (00858): MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS | - | HKEx | ||
| 28.11.25 | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 20.11.25 | EXTRAWELL PHAR (00858): PROFIT WARNING | 2 | HKEx |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 64,04 | 0,00 % | Biogen posts mid-stage trial data for Alzheimer's candidate developed with Ionis | ||
| CSPC PHARMA | 0,882 | +0,67 % | CSPC PHARMA (01093): DATE OF BOARD MEETING | ||
| SELLAS LIFE SCIENCES | 5,600 | +0,36 % | SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses | ||
| ACADIA PHARMACEUTICALS | 19,175 | +1,29 % | Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results | ||
| CATALYST PHARMACEUTICALS | 26,600 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 430,70 | -2,84 % | Truist raises Madrigal Pharmaceuticals stock price target on MASH survey | ||
| OPUS GENETICS | 4,320 | 0,00 % | Citizens cuts Opus Genetics stock price target on share dilution | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,468 | -0,64 % | Savara Inc - 10-Q, Quarterly Report | ||
| GALECTIN THERAPEUTICS | 1,880 | 0,00 % | Galectin publishes phase 2b trial results in Hepatology | ||
| BIODEXA PHARMACEUTICALS | 3,660 | -1,48 % | XFRA 5MP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIODEXA PHARMA ADR... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,033 | -1,49 % | Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study | ||
| CIPHER PHARMACEUTICALS | 10,700 | 0,00 % | Cipher Pharmaceuticals GAAP EPS of $0.24 beats by $0.10, revenue of $12.51M beats by $0.31M | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| VASO | - | - | VASO Corp - 8-K, Current Report |
Das Unternehmen EXTRAWELL PHARMACEUTICAL HOLDINGS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.